The European Commission and German biotech firm, CureVac, on Thursday, August 20, 2020 said they had concluded a first round of talks for the supply of no less than 225 million doses of a potential COVID-19 vaccine to EU member states.
The EU’s executive arm is also in talks with Johnson & Johnson and Sanofi for their vaccines under development.
Recently, the commission agreed an advanced purchase deal with AstraZeneca for no less than 300 million doses of the shot it is developing with Oxford University.
“Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus.
“We will soon have an agreement with CureVac,” the EU Commission President Ursula von der Leyen said, confirming a Reuters report in July.
The EU will now begin negotiating a contract with CureVac, which could be the company’s first bilateral supply deal, aimed at securing the vaccine for all 27 EU member states should the shot prove safe and effective.
CureVac said that the talks included an option to supply 180 million additional doses.
The company’s shares rose almost 8 per cent in premarket trade, having soared as much as 222 per cent after its Nasdaq debut on Friday, the first by a company developing a COVID-19 vaccine.
EU officials told Reuters in July that the Commission was also in talks with U.S. biotech firm Moderna and German firm BioNtech, which is developing a vaccine with U.S. pharmaceutical company Pfizer.
CureVac’s approach is based on so-called messenger RNA, pieces of genetic code that prompt human cells to produce therapeutic proteins.
Moderna and BionTech are using similar technology.
CureVac said it could start large-scale human trials on its vaccine in the last quarter of this year based on results of its current trials.
“The Commission said funding would be provided through an EU emergency fund, of which around €2 billion ($2.37 billion) can be used to finance advance purchase deals,’’ officials told Reuters.
In its talks with vaccine makers, the EU usually offers to finance some upfront development costs in exchange for the right to quickly obtain doses of successful candidates.
Actual purchases would be decided at a later stage by each EU state.